Intraarterial chemotherapy for osteosarcoma: does the result really justify the effort?

Area of Science:

• Oncology
• Pharmacology
• Surgical Oncology

Background:

• Multiagent chemotherapy improves survival for osteosarcoma patients.
• Intraarterial cisplatin infusion has been proposed to enhance primary tumor drug levels.
• Previous studies have not confirmed increased platinum deposition in osteosarcoma tissue via this route.

Purpose of the Study:

• To evaluate the efficacy and clinical outcomes of intraarterial versus intravenous cisplatin administration in osteosarcoma treatment.
• To determine if the intraarterial route offers superior tumor response or improved patient survival.
• To assess the overall benefit-risk profile of intraarterial cisplatin infusion.

Main Methods:

• Review of comparative studies and controlled trials (e.g., COSS 86) examining cisplatin administration routes.
• Analysis of clinical data correlating cisplatin route with tumor response and patient survival.
• Consideration of systemic drug levels, tissue platinum content, side effects, and treatment costs.

Main Results:

• No correlation was found between the route of cisplatin administration (intraarterial vs. intravenous) and tumor response to chemotherapy.
• Controlled studies did not demonstrate a benefit of intraarterial cisplatin in terms of clinical results or survival.
• Systemic drug levels are not compromised, but increased platinum in tumor tissue remains unsubstantiated.

Conclusions:

• Intraarterial cisplatin administration for osteosarcoma is an investigational approach, not standard therapy.
• This regional method lacks proven clinical benefits and does not enhance chemotherapy response.
• Potential risks, increased costs, and lack of demonstrated advantages necessitate careful consideration before its use.